Biotechnology

FOMAT Becomes Largest Embedded Research Organization in the U.S. with Acquisition of Topography Health's Research Sites

May 1, 2026 10:05 AM

FOMAT Medical Research, an Embedded Research Organization (ERO) focused on expanding access to clinical trials, today announced it has acquired Topography Health's research site business unit, a U.S.-based clinical research enablement company that brings trials into community-based physician practices. Financial terms of the deal were not disclosed. The acquisition expands FOMAT's network to more than 35 sites across six states - Maryland,...

Read more

Cloud-Clone Supports Groundbreaking Cell Metabolism Study: Gut Microbial Metabolite Promotes Fat Thermogenesis via Immune System

April 30, 2026 12:00 PM

A groundbreaking study published in the prestigious journal Cell Metabolism (IF=30.9) has revealed a novel signaling axis connecting gut microbiota, immune cells, and progenitor adipocytes, offering a fresh target for metabolic disease intervention. The study demonstrates that cold exposure significantly increases the levels of Prevotella copri and its metabolic product, 3-phenylpropionic acid (3-PPA), which activates communication between...

Read more

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

April 30, 2026 9:15 AM

OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an overview of the Company's landmark VXM01 global licensing agreement and its implications for OSRH shareholders. Virtual Presentation Details Date: May 7,...

Read more

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

April 30, 2026 7:40 AM

Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced its participation in the Pediatric Endocrine Society (PES) Annual Meeting, taking place April 30 to May 3, 2026, in San Francisco, CA, USA. Egetis will engage with the pediatric endocrinology community through multiple scientific and educational activities during the meeting. The Company will host a disease...

Read more

New ESMO Data Highlights TKa Across Multiple Treatment Settings

April 30, 2026 6:30 AM

Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) - Biovica today announces that three posters including TKa measurements will be presented at ESMO Breast in Berlin on 6-8 May 2026. The presentations highlight how TKa can be used to monitor treatment response, disease progression and biological treatment effect across several clinically relevant settings in metastatic breast cancer. For Biovica, the presentations further underline...

Read more

ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026

April 29, 2026 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 first quarter on Wednesday, May 13th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 first quarter results on Wednesday, May 13th, at 4:30 p.m....

Read more

Resolutions at BioInvent's Annual General Meeting 2026

April 29, 2026 12:00 PM

The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new Board members, re-elect the Board members Natalie Berner, Leonard Kruimer, Nanna Lüneborg and Bernd Seizinger, and to implement, inter alia, a long-term incentive program. The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the...

Read more

FBB Biomed Submits First Scientific Manuscript on Its Systems-Biology Platform for Long COVID

April 29, 2026 11:45 AM

FBB Biomed, a privately held biomedical company developing a systems biology-based RNA intelligence platform, announced today that it has submitted its first scientific manuscript for peer-reviewed publication. The manuscript, titled "Multi-biosystem dysregulation in neurologic post-acute sequelae of SARS-CoV-2 infection (PASC)," describes the company's proprietary approach to characterizing patients with PASC (long COVID) through a coordinated,...

Read more

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

April 29, 2026 9:50 AM

OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2. The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across...

Read more

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

April 29, 2026 8:05 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Company the first-ever IDE approval to proceed with a U.S. pivotal study of a non-surgical replacement venous valve. The Transcatheter Venous Valve Endoprosthesis (TAVVE®) pivotal study will evaluate the Company's...

Read more

BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio

April 29, 2026 5:55 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, will host two Key Opinion Leader (KOL) events in the coming weeks, highlighting scientific and clinical progress across its BI-1808 and BI-1206 programs. Virtual KOL Event: BI‑1808 for the treatment of solid tumors BioInvent will host a virtual KOL event focused on BI-1808, the Company's novel anti‑TNFR2 antibody,...

Read more

Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference

April 29, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present multiple posters at the 2026 American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida from May 15 - May 20, 2026. The abstracts include analyses from the completed Phase 2a...

Read more

BioInvent International AB: Interim Report January - March 2026

April 29, 2026 2:20 AM

BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent. EVENTS IN THE FIRST QUARTER (R) Promising data in ongoing Phase 2a...

Read more

LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

April 28, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce, further to its news release dated January 22, 2026, the launch of its previously designed controlled ex vivo porcine skin study, which is intended to evaluate whether protamine can enhance the penetration of macromolecular therapeutics across the skin. This announcement follows the Company's recent completion of the...

Read more

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

April 28, 2026 12:15 PM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced its participation in the caregiver-focused podcast Autumn Is Here, as part of its broader effort to increase awareness of agitation associated with Alzheimer's disease and support patient engagement in its ongoing Phase 2 CALMA clinical trial, which has recently reached...

Read more

NatureCell Initiates FDA-Cleared Phase 2b Alzheimer's Trial and Accelerates Clinical Development

April 28, 2026 8:00 AM

NatureCell Co., Ltd. (KOSDAQ: 007390) announced the planned reactivation and acceleration of its previously cleared Phase 2b clinical trial for Alzheimer's disease under an Investigational New Drug (IND) authorization from the U.S. Food and Drug Administration (FDA). The study is designed to evaluate autologous adipose-derived mesenchymal stem cells (AD-MSCs) administered via repeated intravenous infusions, as a potential disease-modifying...

Read more

Invitation to Alligator Bioscience's Earnings Call on 5 May 2026

April 28, 2026 2:50 AM

Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, will publish its interim report for the period 1 January - 31 March 2026 on Thursday, 5 May 2026, at 8:00 a.m. CEST. On the same day, Alligator will host a webinar and conference call for investors, analysts, and media at 1:00 p.m. CEST / 7:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and...

Read more

Bio Essence Corporation (OTCQB: BIOE) to Acquire MediFlow AI Platform, Strengthening Its Human Health and Wellness Portfolio

April 27, 2026 8:00 AM

Bio Essence Corporation (OTCQB:BIOE) ("Bio Essence" or the "Company"), a specialized health and wellness provider, today announced that it has entered into a definitive Asset Purchase Agreement to acquire the MediFlow AI platform from Zhituo Software Co., Limited. MediFlow AI is an advanced technology platform built to provide data-driven wellness and lifestyle solutions for human use. By integrating this platform, Bio Essence enhances its...

Read more

Microbix Product Results Being Presented at 2026 PASCV

April 27, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that one of its clients is presenting results of Microbix made quality assessment products ("QAPs™") that help enable full-process quality management of molecular assays to detect human papillomavirus ("HPV") at 2026 PASCV. 2026 PASCV is the annual meeting and principal gathering of the Pan American Society for Clinical...

Read more

Four Independent Studies Validate The Blight Tolerance Of Darling American Chestnut Trees

April 25, 2026 12:30 PM

Today, SilvaBio, in collaboration with academic partners, reports findings from four independent experiments demonstrating that transgenic American chestnut trees consistently tolerate blight, the fungal disease that rendered the species functionally extinct in the early 19th century. This expanding body of evidence-spanning studies conducted by Purdue University, the University of New England (UNE) and SUNY College of Environmental Science and...

Read more